← Leaderboards
Sallie R. Permar
Boston Children'S Hospital
$59,901,483
Attributed
$69,031,869
Total exposure
56
Grants
54
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $18.6M · FY2009–25$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$130,890,834 · 61
By mechanism
P01$89,895,338 · 37
R01$20,366,605 · 7
K12$10,558,677 · 1
DP2$2,832,000 · 1
R38$2,759,997 · 3
R21$2,444,704 · 6
Top collaborators
- Kristina Abel16 shared
- Genevieve Giny Fouda Amou Ou5 shared
- Matthew Scott Kelly5 shared
- David H Harpole4 shared
- Amitinder Kaur4 shared
- Scott M Palmer4 shared
- Roger Keith Reeves4 shared
- Peter A Barry3 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Joel N Hirschhorn$22,642,169
- Judy Lieberman$53,446,005
- Jose Manuel Ordovas-Montanes$2,723,428
- Garnett H Kelsoe$38,441,709
Others in their field
Top investigators on “Transmission Process”
- Lawrence Corey · Fred Hutchinson Cancer Center$395,692,425
- Barton F Haynes · Duke University$361,523,708
- Myron S Cohen · Family Health International$234,988,190
- Wafaa M. El-Sadr · Columbia University Health Sciences$228,712,583
- Richard Webby · St. Jude Children'S Research Hospital$182,265,847
- Barbara Driver · Westat, Inc.$169,952,152
Research focus
Transmission ProcessInfectionVirusProgramsVaccinesMacaca MulattaImmune ResponsePreventInfantDesignImmuneResponseViralImmunologicsAntibodiesNonhuman PrimateImmunityVaccinationNeutralizing AntibodyBaseVaccine DevelopmentResourcesPreventionHiv-1
Grant awards (189)
Translating germline-targeting HIV Env SOSIP immunization of infants: targeting bnAbs in early life$4,630,686
P01 · FY2025 · AI · contact PI
Immunologic strategies to prevent congenital cytomegalovirus transmission and disease in rhesus monkeys$4,302,307
P01 · FY2025 · AI · contact PI
Model Systems Core (MODS Core)$2,034,255
P01 · FY2025 · AI · contact PI
Pediatric Scientist Development Program$1,611,621
K12 · FY2025 · HD · contact PI
Determinants of HIV broadly-neutralizing antibody precursor induction in infants$1,516,969
P01 · FY2025 · AI
Early life B cell responses and inflammation following SARS-CoV-2 infection$838,453
R01 · FY2025 · AI
Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infection$794,563
R01 · FY2025 · AI · contact PI
Role of maternal-fetal interface NK cells in pregnancy maintenance and congenital CMV transmission$698,695
R01 · FY2025 · HD · contact PI
Administrative Core$591,149
P01 · FY2025 · AI · contact PI
Dose, interval, and adjuvant optimization of HIV Env SOSIP GT1.1 for administration in early life$466,335
P01 · FY2025 · AI · contact PI
Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)$448,897
R38 · FY2025 · AI
Efficacy of CMV vFcR vaccines to prevent congenital CMV transmission$279,311
P01 · FY2025 · AI · contact PI
Administrative Core$193,042
P01 · FY2025 · AI · contact PI
Improving HCMV vaccine-elicited immunity by targeting viral Fc receptors$181,657
R21 · FY2025 · AI · contact PI
Immunologic strategies to prevent congenital cytomegalovirus transmission and disease in rhesus monkeys$4,199,924
P01 · FY2024 · AI · contact PI
Model Systems Core (MODS Core)$1,840,878
P01 · FY2024 · AI · contact PI
Determinants of HIV broadly-neutralizing antibody precursor induction in infants$1,518,131
P01 · FY2024 · AI
Pediatric Scientist Development Program$1,501,572
K12 · FY2024 · HD · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,370,057
P01 · FY2024 · AI · contact PI
Early life B cell responses and inflammation following SARS-CoV-2 infection$852,895
R01 · FY2024 · AI
Escape of maternal plasma broadly neutralizing antibody as a mechanism of mother to child HIV transmission$828,185
R01 · FY2024 · AI · contact PI
Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infection$822,260
R01 · FY2024 · AI · contact PI
Role of maternal-fetal interface NK cells in pregnancy maintenance and congenital CMV transmission$699,071
R01 · FY2024 · HD · contact PI
Project-002$668,200
P01 · FY2024 · AI · contact PI
Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)$448,897
R38 · FY2024 · AI
Core-001$435,818
P01 · FY2024 · AI · contact PI
Efficacy of CMV vFcR vaccines to prevent congenital CMV transmission$307,383
P01 · FY2024 · AI · contact PI
Admin-Core-001$266,039
P01 · FY2024 · AI · contact PI
Improving HCMV vaccine-elicited immunity by targeting viral Fc receptors$247,025
R21 · FY2024 · AI · contact PI
Administrative Core$182,777
P01 · FY2024 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$2,755,195
P01 · FY2023 · AI · contact PI
Pediatric Scientist Development Program$1,650,000
K12 · FY2023 · HD · contact PI
Determinants of HIV broadly-neutralizing antibody precursor induction in infants$1,584,559
P01 · FY2023 · AI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,381,667
P01 · FY2023 · AI · contact PI
Core-001$1,135,654
P01 · FY2023 · AI · contact PI
Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infection$848,374
R01 · FY2023 · AI · contact PI
Escape of maternal plasma broadly neutralizing antibody as a mechanism of mother to child HIV transmission$835,206
R01 · FY2023 · AI · contact PI
Role of maternal-fetal interface NK cells in pregnancy maintenance and congenital CMV transmission$711,943
R01 · FY2023 · HD · contact PI
Early life B cell responses and inflammation following SARS-CoV-2 infection$706,463
R01 · FY2023 · AI
Core-002$541,944
P01 · FY2023 · AI · contact PI
Project-002$509,059
P01 · FY2023 · AI · contact PI
Nonhuman Primate Core (NHP Core/Core 1)$480,199
P01 · FY2023 · AI · contact PI
Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)$448,897
R38 · FY2023 · AI
Core-003$301,825
P01 · FY2023 · AI · contact PI
Project-003$252,702
P01 · FY2023 · AI · contact PI
Core-002$222,502
P01 · FY2023 · AI · contact PI
Administrative Core$221,517
P01 · FY2023 · AI · contact PI
Core-004$204,337
P01 · FY2023 · AI · contact PI
Admin-Core-002$138,007
P01 · FY2023 · AI · contact PI
Admin-Core-001$129,116
P01 · FY2023 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$2,902,791
P01 · FY2022 · AI · contact PI
Pediatric Scientist Development Program$1,535,726
K12 · FY2022 · HD · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,375,878
P01 · FY2022 · AI · contact PI
Escape of maternal plasma broadly neutralizing antibody as a mechanism of mother to child HIV transmission$839,636
R01 · FY2022 · AI · contact PI
Early life B cell responses and inflammation following SARS-CoV-2 infection$762,710
R01 · FY2022 · AI
Role of maternal-fetal interface NK cells in pregnancy maintenance and congenital CMV transmission$754,314
R01 · FY2022 · HD · contact PI
Project-002$621,661
P01 · FY2022 · AI · contact PI
Core-004$498,833
P01 · FY2022 · AI · contact PI
Nonhuman Primate Core (NHP Core/Core 1)$343,970
P01 · FY2022 · AI · contact PI
Administrative Core$343,970
P01 · FY2022 · AI · contact PI
Project 1: Age-related impact on early life B cell lineage-designed SOSIP HIV Env vaccination$343,969
P01 · FY2022 · AI · contact PI
Core-001$279,994
P01 · FY2022 · AI · contact PI
Project-003$265,576
P01 · FY2022 · AI · contact PI
Core-003$141,703
P01 · FY2022 · AI · contact PI
Admin-Core-001$127,972
P01 · FY2022 · AI · contact PI
Project-002$14,107
P01 · FY2022 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$14,107
P01 · FY2022 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$2,948,233
P01 · FY2021 · AI · contact PI
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys$1,438,174
P01 · FY2021 · AI · contact PI
Pediatric Scientist Development Program$1,409,636
K12 · FY2021 · HD · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,397,532
P01 · FY2021 · AI · contact PI
Core-001$1,082,643
P01 · FY2021 · AI · contact PI
Early life B cell responses and inflammation following SARS-CoV-2 infection$854,272
R01 · FY2021 · AI
Escape of maternal plasma broadly neutralizing antibody as a mechanism of mother to child HIV transmission$744,209
R01 · FY2021 · AI · contact PI
Project-002$580,789
P01 · FY2021 · AI · contact PI
Core-003$533,410
P01 · FY2021 · AI · contact PI
Nonhuman Primate Core (NHP Core/Core 1)$339,713
P01 · FY2021 · AI · contact PI
Core-002$325,038
P01 · FY2021 · AI · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$299,339
P01 · FY2021 · AI · contact PI
Project-003$258,074
P01 · FY2021 · AI · contact PI
Project 1: Age-related impact on early life B cell lineage-designed SOSIP HIV Env vaccination$242,755
P01 · FY2021 · AI · contact PI
Administrative and Statistical Core$178,063
P01 · FY2021 · AI · contact PI
Core-004$168,279
P01 · FY2021 · AI · contact PI
Administrative Core$100,879
P01 · FY2021 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$91,927
P01 · FY2021 · AI · contact PI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$35,539
P01 · FY2021 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$2,860,280
P01 · FY2020 · AI · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,307,799
P01 · FY2020 · AI · contact PI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$1,227,827
P01 · FY2020 · AI · contact PI
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys$1,163,936
P01 · FY2020 · AI · contact PI
Core 1: Nonhuman Primate Core$1,039,734
P01 · FY2020 · AI · contact PI
Pediatric Scientist Development Program$875,030
K12 · FY2020 · HD · contact PI
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys$694,562
P01 · FY2020 · AI · contact PI
Pediatric Scientist Development Program (K12) 2017-2022$550,031
K12 · FY2020 · HD · contact PI
Core 2: Virology, Molecular, and Histology Core$453,807
P01 · FY2020 · AI · contact PI
Project 1: Immune correlates of cCMV$405,123
P01 · FY2020 · AI · contact PI
Nonhuman Primate Core (NHP Core/Core 1)$354,930
P01 · FY2020 · AI · contact PI
Core 3: Genomic Sequencing and Population Genetics Core$338,605
P01 · FY2020 · AI · contact PI
Project 2: Virologic determinants of cCMV$250,306
P01 · FY2020 · AI · contact PI
Project 1: Age-related impact on early life B cell lineage-designed SOSIP HIV Env vaccination$244,720
P01 · FY2020 · AI · contact PI
Administrative Core$229,676
P01 · FY2020 · AI · contact PI
Humoral Immune Correlates of Protection against Congenital CMV and HSV Transmission in HIV-Infected Women$192,957
R21 · FY2020 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$188,956
P01 · FY2020 · AI · contact PI
Administrative Core$161,398
P01 · FY2020 · AI · contact PI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$137,491
P01 · FY2020 · AI · contact PI
Administrative and Statistical Core$101,338
P01 · FY2020 · AI · contact PI
Administrative and Statistical Core$61,486
P01 · FY2020 · AI · contact PI
Core 1: Nonhuman Primate Core$59,219
P01 · FY2020 · AI · contact PI
Core 2: Virology, Molecular, and Histology Core$35,027
P01 · FY2020 · AI · contact PI
Core 3: Genomic Sequencing and Population Genetics Core$33,789
P01 · FY2020 · AI · contact PI
Humoral immune correlates of protection against congenital CMV and HSV transmission in HIV-infected women$29,470
R21 · FY2020 · AI · contact PI
Project 1: Immune correlates of cCMV$27,990
P01 · FY2020 · AI · contact PI
Project 2: Virologic determinants of cCMV$21,517
P01 · FY2020 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$12,517
P01 · FY2020 · AI · contact PI
Administrative Core$6,996
P01 · FY2020 · AI · contact PI
Core 1: Nonhuman Primate Core$3,851
P01 · FY2020 · AI · contact PI
Core 2: Virology, Molecular, and Histology Core$2,303
P01 · FY2020 · AI · contact PI
Core 3: Genomic Sequencing and Population Genetics Core$2,221
P01 · FY2020 · AI · contact PI
Project 1: Immune correlates of cCMV$1,914
P01 · FY2020 · AI · contact PI
Project 2: Virologic determinants of cCMV$1,414
P01 · FY2020 · AI · contact PI
Administrative Core$496
P01 · FY2020 · AI · contact PI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$2,863,852
P01 · FY2019 · AI · contact PI
Maternal and infant immunization to eliminate breast milk transmission of HIV-1$2,101,177
P01 · FY2019 · AI · contact PI
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys$1,646,529
P01 · FY2019 · AI · contact PI
Pediatric Scientist Development Program (K12) 2017-2022$1,425,061
K12 · FY2019 · HD · contact PI
Core 1: Nonhuman Primate Core$998,573
P01 · FY2019 · AI · contact PI
Unified Program for Therapeutics in Children (UPTiC)$502,105
T32 · FY2019 · HD · contact PI
Core 3: Genomic Sequencing and Population Genetics Core$486,980
P01 · FY2019 · AI · contact PI
Project 1: Immune correlates of cCMV$430,637
P01 · FY2019 · AI · contact PI
Project 2: Virologic determinants of cCMV$385,388
P01 · FY2019 · AI · contact PI
Duke Resident Physician-Scientist Program- NIAID$355,808
R38 · FY2019 · AI · contact PI
Duke Resident Physician-Scientist Program- NHLBI$350,114
R38 · FY2019 · HL · contact PI
Core 2: Virology, Molecular, and Histology Core$324,737
P01 · FY2019 · AI · contact PI
Development of a maternal vaccine to protect infants against clade C HIV-1$291,430
P01 · FY2019 · AI · contact PI
Humoral immune correlates of protection against congenital CMV and HSV transmission in HIV-infected women$255,813
R21 · FY2019 · AI · contact PI
Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination$197,407
R21 · FY2019 · AI · contact PI
Administrative Core$163,614
P01 · FY2019 · AI · contact PI
Administrative Core$154,800
P01 · FY2019 · AI · contact PI
Administrative and Statistical Core$144,905
P01 · FY2019 · AI · contact PI
Maternal and infant immunization to eliminate breast milk transmission of HIV-1$2,336,538
P01 · FY2018 · AI · contact PI
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys$1,651,483
P01 · FY2018 · AI · contact PI
Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT$665,182
R01 · FY2018 · AI · contact PI
Innate antiviral factors in breast milk and the oral HIV-1 reservoir$627,756
R01 · FY2018 · DE · contact PI
Administrative and Statistical Core$537,768
P01 · FY2018 · AI · contact PI
Duke Resident Physician-Scientist Program- NIAID$353,784
R38 · FY2018 · AI · contact PI
Duke Resident Physician-Scientist Program- NHLBI$353,600
R38 · FY2018 · HL · contact PI
Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination$251,267
R21 · FY2018 · AI · contact PI
The relationship between maternal ZIKV-specific and ADE antibodies and fetal outcome$225,608
R21 · FY2018 · AI · contact PI
Development of a maternal vaccine to protect infants against clade C HIV-1$203,437
P01 · FY2018 · AI · contact PI
Administrative Core$131,027
P01 · FY2018 · AI · contact PI
Maternal and infant immunization to eliminate breast milk transmission of HIV-1$2,263,268
P01 · FY2017 · AI · contact PI
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys$1,698,360
P01 · FY2017 · AI · contact PI
Innate antiviral factors in breast milk and the oral HIV-1 reservoir$645,686
R01 · FY2017 · DE · contact PI
Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT$608,706
R01 · FY2017 · AI · contact PI
Transmission-blocking potential of novel HIV Env-specific mucosal antibodies$602,061
R01 · FY2017 · AI · contact PI
Maternal immune protection against congenital CMV infection$477,000
DP2 · FY2017 · HD · contact PI
Administrative Core$314,550
P01 · FY2017 · AI · contact PI
Development of a maternal vaccine to protect infants against clade C HIV-1$192,092
P01 · FY2017 · AI · contact PI
Administrative and Statistical Core$118,934
P01 · FY2017 · AI · contact PI
Maternal and infant immunization to eliminate breast milk transmission of HIV-1$2,532,602
P01 · FY2016 · AI · contact PI
Maternal and infant immunization to eliminate breast milk transmission of HIV-1$1,141,522
P01 · FY2016 · AI · contact PI
Transmission-blocking potential of novel HIV Env-specific mucosal antibodies$767,068
R01 · FY2016 · AI · contact PI
Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT$623,456
R01 · FY2016 · AI · contact PI
Innate antiviral factors in breast milk and the oral HIV-1 reservoir$614,796
R01 · FY2016 · DE · contact PI
Development of a maternal vaccine to protect infants against clade C HIV-1$297,271
P01 · FY2016 · AI · contact PI
Development of a maternal vaccine to protect infants against clade C HIV-1$196,047
P01 · FY2016 · AI · contact PI
Administrative Core$125,281
P01 · FY2016 · AI · contact PI
Maternal and infant immunization to eliminate breast milk transmission of HIV-1$2,440,281
P01 · FY2015 · AI · contact PI
Transmission-blocking potential of novel HIV Env-specific mucosal antibodies$769,549
R01 · FY2015 · AI · contact PI
Innate antiviral factors in breast milk and the oral HIV-1 reservoir$594,774
R01 · FY2015 · DE · contact PI
Development of a maternal vaccine to protect infants against clade C HIV-1$183,841
P01 · FY2015 · AI · contact PI
Administrative Core$150,724
P01 · FY2015 · AI · contact PI
Transmission-blocking potential of novel HIV Env-specific mucosal antibodies$782,229
R01 · FY2014 · AI · contact PI
A novel HIV-1-neutralizing protein isolated from breast milk$196,250
R21 · FY2014 · AI · contact PI
Transmission-blocking potential of novel HIV Env-specific mucosal antibodies$474,093
R01 · FY2013 · AI · contact PI
A novel HIV-1-neutralizing protein isolated from breast milk$235,500
R21 · FY2013 · AI · contact PI
Antibody protection against SIV transmission$196,250
R21 · FY2013 · AI · contact PI
Vaccine-induced HIV antibody responses in infants$74,497
R03 · FY2013 · HD · contact PI
SIV-specific Immunity in breast milk during infection and after vaccination$38,700
K08 · FY2013 · AI · contact PI
Maternal immune protection against congenital CMV infection$2,355,000
DP2 · FY2012 · HD · contact PI
Antibody protection against SIV transmission$235,500
R21 · FY2012 · AI · contact PI
SIV-specific Immunity in breast milk during infection and after vaccination$132,300
K08 · FY2012 · AI · contact PI
Vaccine-induced HIV antibody responses in infants$78,500
R03 · FY2012 · HD · contact PI
Breast Milk Studies$676,337
U19 · FY2011 · AI · contact PI
SIV-specific Immunity in breast milk during infection and after vaccination$132,300
K08 · FY2011 · AI · contact PI
SIV INFECTION AND VACCINATION IN LACTATING MONKEYS$68,415
P51 · FY2011 · RR · contact PI
SIV-specific Immunity in breast milk during infection and after vaccination$132,300
K08 · FY2010 · AI · contact PI
SIV INFECTION AND VACCINATION IN LACTATING MONKEYS$65,759
P51 · FY2010 · RR · contact PI
SIV-specific Immunity in breast milk during infection and after vaccination$132,300
K08 · FY2009 · AI · contact PI